Clik here to view.
Amgen, Unilife extend talks on exclusivity deal
Unilife (NSDQ:UNIS) and Amgen (NSDQ:AMGN) are giving themselves to the end of the week to come to an agreement on whether their deal for Unilife’s wearable injector technology will be exclusive to...
View ArticleClik here to view.
Unilife, Amgen extend exclusivity negotiations again
Unilife (NSDQ:UNIS) and Amgen (NSDQ:AMGN) are giving themselves another week to come to an agreement on whether their deal for Unilife’s wearable injector technology will be exclusive to Amgen. UNIS...
View ArticleClik here to view.
Unilife, Amgen extend negotiations a 3rd time
Unilife (NSDQ:UNIS) and Amgen (NSDQ:AMGN) are tacking on another 11 days to come to an agreement on whether their deal for Unilife’s wearable injector technology will be exclusive to Amgen or not. The...
View ArticleClik here to view.
Baxter to further trim stake in Baxalta ahead of $32B Shire buyout
Baxter (NYSE:BAX) plans to further trim its stake in Baxalta (NYSE:BXLT), the biopharm business it spun out last year, reducing its ownership to 5.1% ahead of Baxalta’s $32 billion takeover by Shire...
View ArticleClik here to view.
Now there’s proof: Docs who get company cash tend to prescribe more...
by Charles Ornstein, Ryann Grochowski Jones and Mike Tigas, ProPublica. Doctors have long disputed that the payments they receive from pharmaceutical companies have any relationship to how they...
View ArticleClik here to view.
Capsugel said to explore sale, IPO
Capsugel‘s private equity owner is said to be exploring a sale or initial public offering for the Pfizer (NYSE:PFE) spinout. A deal could value Capsugel, which makes hard capsules and drug delivery...
View ArticleClik here to view.
Baxter boosts Baxalta share exchange offer
Baxter (NYSE:BAX) said today that its raising the size of its offer to exchange its own shares for those of its Baxalta (NYSE: BXLT) pharmaceuticals spinout ahead of its acquisition by Shire...
View ArticleClik here to view.
Ligand Pharmaceuticals pays $18m for CorMatrix assets
Ligand Pharmaceuticals (NSDQ:LGND) said this week that it’s getting into the medical device arena with the nearly $18 million acquisition of multiple tissue repair assets from CorMatrix. San...
View ArticleClik here to view.
Baxter said to be front-runner in $1.2B race for India’s Gland Pharma
Baxter (NYSE:BAX) is the front-runner in the chase for has emerged as the frontrunner to buy India’s Gland Pharma for as much as $1.2 billion, according to the Economic Times. Hyderabad-based Gland,...
View ArticleClik here to view.
Otsuka gets in on ReCor Medical’s Paradise renal denervation device
ReCor Medical said it landed a strategic investment from Japanese conglomerate Otsuka Pharmaceutical (TYO:4578) that will bring to Asia its Paradise renal denervation device for treating hypertension....
View ArticleClik here to view.
Report: GE Healthcare CEO Flannery turns his eye from M&A to internal growth
GE Healthcare (NYSE:GE) CEO John Flannery, who oversaw more than $26 billion in deals during his tenure as the conglomerate’s business development leader, is reportedly looking to a different playbook...
View ArticleClik here to view.
Strong earnings help Consort Medical recover from hit by delay in Mylan approval
Consort Medical (LON:CSRT) said the impending launch of a generic Advair inhaler by Mylan (NSDQ:MYL) represents a significant opportunity for its Bespak drug delivery device unit, but analysts were...
View ArticleClik here to view.
DelMar, Accurexa ink deal for chemotherapy combo
DelMar Pharmaceuticals and Accurexa said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer. The agreement calls for DelMar to supply the...
View ArticleClik here to view.
GE plans ‘lab-in-a-box’ complex in Ireland
GE (NYSE:GE) reportedly plans to build 4 prefabricated drug factories in Cork, Ireland. The U.S.-based company said yesterday that it plans to put $167 million (€150 million) into a biopharmaceutical...
View ArticleClik here to view.
Innovation & investment needed in drug delivery tech
When Menashe Levy was working on his Ph.D. from the Hebrew University of Jerusalem in the mid-80s, he encountered the very first renderings of innovation in drug delivery: controlled, sustained release...
View ArticleClik here to view.
Mylan CEO testifies before Senate about EpiPen pricing
Mylan CEO Heather Bresch testified before Senate yesterday after the Oversight and Government Reform Committee expressed concerns about the company’s price increases of its epinephrine auto-injector....
View ArticleClik here to view.
Ocular therapeutics company Novaliq names new CEO
Novaliq GmbH said yesterday that it named Christian Roesky as its new CEO, replacing co-founder Bernhard Günther, who will take on a new role as chief innovation officer. The Heidelberg, Germany-based...
View ArticleClik here to view.
Tunable hydrogel helps predict tissue response to chemo
Researchers from the Wyss Institute have developed a hydrogel microenvironment to evaluate how physical properties like stiffness of the extracellular matrix impacts the efficacy of chemotherapy. “To...
View ArticleClik here to view.
Hospital survey shows inpatient drug prices rose 40% in 2 years
A community hospital survey sponsored by the American Hospital Assn. and the Federation of American Hospitals shows that inpatient drug prices rose 40% between 2013 and 2015. Almost all of the surveyed...
View ArticleClik here to view.
Cardinal Health cuts outlook after pharma segment profits fall
Shares in Cardinal Health (NYSE:CAH) rose slightly yesterday after the prescription drug distributor met expectations on Wall Street with its 1st-quarter results, despite the company’s pharma segment...
View Article